Mobile Health Solution for Wafarin Management

Tuesday, November 13, 2012 - 6:30pm

 

Team GenovoTechWarfarin, an anticoagulant, has been actively prescribed for over 60 years, with approximately 4 million Americans currently taking Warfarin. Despite this, there are continuous safety issues associated with Warfarin treatment as patients spend an average of only 57% to 66% of their treatment time in the narrow therapeutic range. Moreover, Warfarin interacts with numerous drugs as well as with foods of high vitamin K content.  Because of this, Warfarin is classified as one of the top 10 drugs most frequently reported for adverse events.  Therapeutic maintenance has proven problematic, requiring regular physician visits to adjust the user’s Warfarin dosage. Currently, there is a growing trend among healthcare practitioners to shift treatment focus to encourage patient self-management (PSM).  In line with this new paradigm, GenovoTech proposes a mobile app that will serve as a self-management tool to assist Warfarin users.  It is comprised of several utilities that will enable users to confidently take control of their treatment, greatly reducing the risk of adverse events and associated mortality.  

 

Sorry, this presentation is NOT open to the public. 

The Master of Biotechnology Program would like to thank AstraZeneca Canada Inc. for their continued support of this seminar series.